BIOCRYST PHARMACTL revenue breakdown overview

BIOCRYST PHARMACTL revenue for the last year amounted to 279.03 M CHF, the most of which — 279.03 M CHF — came from its highest performing source at the moment, Oral Small Molecule and Protein Therapeutics, the year earlier bringing 250.44 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought BIOCRYST PHARMACTL 242.78 M CHF.